MX2019006728A - Nuevo proceso. - Google Patents

Nuevo proceso.

Info

Publication number
MX2019006728A
MX2019006728A MX2019006728A MX2019006728A MX2019006728A MX 2019006728 A MX2019006728 A MX 2019006728A MX 2019006728 A MX2019006728 A MX 2019006728A MX 2019006728 A MX2019006728 A MX 2019006728A MX 2019006728 A MX2019006728 A MX 2019006728A
Authority
MX
Mexico
Prior art keywords
novel process
compositions
sterol
saponin
maturation
Prior art date
Application number
MX2019006728A
Other languages
English (en)
Inventor
Cara Philippe
Monique Roberte Henderickx Veronique
Martha De Cupere Vinciane
Bertha Ghislaine DE KESEL Carine
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1620758.1A external-priority patent/GB201620758D0/en
Priority claimed from GBGB1708734.7A external-priority patent/GB201708734D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2019006728A publication Critical patent/MX2019006728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención proporciona composiciones, métodos y procesos para la maduración de composiciones de liposoma submicrométricas que comprenden un lípido, un esterol y una saponina.
MX2019006728A 2016-12-07 2017-12-05 Nuevo proceso. MX2019006728A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1620758.1A GB201620758D0 (en) 2016-12-07 2016-12-07 Novel process
GBGB1708734.7A GB201708734D0 (en) 2017-06-01 2017-06-01 Novel process
PCT/EP2017/081546 WO2018104313A1 (en) 2016-12-07 2017-12-05 Novel process

Publications (1)

Publication Number Publication Date
MX2019006728A true MX2019006728A (es) 2019-12-02

Family

ID=60954994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006728A MX2019006728A (es) 2016-12-07 2017-12-05 Nuevo proceso.

Country Status (9)

Country Link
US (1) US10695424B2 (es)
EP (1) EP3551222A1 (es)
JP (1) JP7136777B2 (es)
CN (1) CN110035770B (es)
BE (1) BE1025160B1 (es)
BR (1) BR112019011286A2 (es)
CA (1) CA3045952A1 (es)
MX (1) MX2019006728A (es)
WO (1) WO2018104313A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020055503A1 (en) * 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
WO2022212863A1 (en) 2021-04-01 2022-10-06 Vestaron Corporation Liposome formulations for pesticide delivery and methods for producing and using the same
CN114621357A (zh) * 2022-05-17 2022-06-14 康希诺生物股份公司 一种带状疱疹亚单位疫苗及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69017769T2 (de) 1989-06-27 1995-07-13 Smithkline Beecham Biolog Verbindungen.
DK0614465T3 (da) 1991-11-16 1999-09-27 Smithkline Beecham Biolog Hybridprotein mellem CS fra Plasmodium og HBsAg
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
FR2748748B1 (fr) 1996-05-17 1998-11-06 Pasteur Institut Identification et clonage d'un antigene mycobacterien correspondant a une hemagglutine de liaison a l'heparine
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
EP0975330A1 (en) * 1997-02-04 2000-02-02 Abbott Laboratories Pain reducing parenteral liposome formulation
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
GB0019375D0 (en) 2000-08-07 2000-09-27 Int Centre Genetic Eng & Bio Method of polypeptide renaturation
FR2832410B1 (fr) 2001-11-19 2004-04-02 Pasteur Institut Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1877426B1 (en) 2005-04-29 2012-02-01 GlaxoSmithKline Biologicals SA Method for preventing or treating m tuberculosis infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
SG173377A1 (en) 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
SI2486938T1 (sl) 2006-09-26 2018-09-28 Infectious Disease Research Institute Sestavek cepiva, ki vsebuje sintetični adjuvans
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EA201300102A1 (ru) 2007-05-24 2014-02-28 Глаксосмитклайн Байолоджикалс С.А. Лиофилизированная антигенная композиция
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
KR20110060891A (ko) 2008-07-25 2011-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 신규한 조성물 및 방법
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US20130018178A1 (en) 2009-06-22 2013-01-17 Px Therapeutics Method for the purification of hbha
JP6010463B2 (ja) 2010-01-27 2016-10-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変された結核抗原
EA027920B1 (ru) 2010-12-14 2017-09-29 Глаксосмитклайн Байолоджикалс С.А. Композиция микобактериальных антигенов
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol

Also Published As

Publication number Publication date
BE1025160B1 (fr) 2018-11-26
JP2020500891A (ja) 2020-01-16
CA3045952A1 (en) 2018-06-14
BE1025160A1 (fr) 2018-11-20
WO2018104313A1 (en) 2018-06-14
BR112019011286A2 (pt) 2019-10-15
JP7136777B2 (ja) 2022-09-13
CN110035770A (zh) 2019-07-19
US20200061186A1 (en) 2020-02-27
CN110035770B (zh) 2023-06-16
US10695424B2 (en) 2020-06-30
EP3551222A1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
PH12018500947B1 (en) Crystal form, preparation method and intermediate of dihydropyrido ring compound
MX2022003273A (es) Anticuerpos anti-tau y metodos de uso.
MX2022016566A (es) Composiciones que comprenden una caseina y metodos para producir las mismas.
MX2019006334A (es) Anticuerpos antitau y métodos de uso.
EP3415652A4 (en) ALLOY MEMBER, PROCESS FOR PRODUCING THE ALLOY MEMBER, AND PRODUCT COMPRISING SAID ALLOY ELEMENT
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
GB2577232A8 (en) Methods for manufacturing an adjuvant
MX2019006728A (es) Nuevo proceso.
NZ735362A (en) Lipid compositions
EP3338225A4 (en) SYSTEM AND METHOD FOR PROVIDING A MULTISTANDORTVISUALIZATION AND EVALUATION OF PERFORMANCE IN RELATION TO A SERVICE AGREEMENT
MX2016008851A (es) Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017013855A (es) Metodo para la separacion de proteina y otras impurezas de polisacaridos capsulares microbianos.
FI20165932L (fi) Immunomodulatorisia koostumuksia
PH12018501277A1 (en) Corticosteroid containing foam compositions and method of manufacture thereof
EP3565552A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF RIVAROXABAN INVOLVING A NEW INTERMEDIATE
EP3421463A4 (en) NEW TOXIN AND METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT THEREOF
EP3533779A4 (en) PROCESS FOR PRODUCING TRANS-BIS (2-HYDROXYALKYL) CYCLOHÉXANEDICARBOXYLATE, AND BIS (2-HYDROXYALKYL) CYCLOHÉXANEDICARBOXYLATE
EP3630126A4 (en) CERAMIDE NANOLIPOSOMES, COMPOSITIONS AND METHODS OF USE FOR IMMUNOTHERAPY
EP3563966A4 (en) SURFACE AND MACHINE TRAINING PROCESS
EP3441501A4 (en) CHERRY BLOSSOM PINK DECORATION ELEMENT AND MANUFACTURING METHOD THEREFOR
PH12021551212A1 (en) Process for preparation of anthranilamides
MX2016017019A (es) Metodo para la preparacion de 4-alcoxi-1,1,1-trifluorobut-3-en-2-o nas de 1,1,1 trifluoroacetona.
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
EP3635129B8 (en) Methods for characterizing loss of antigen presentation